Myelodysplastic syndromes: histopathology as prognostic factor

Detalhes bibliográficos
Autor(a) principal: Romeo, Maura [UNIFESP]
Data de Publicação: 2001
Outros Autores: Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP], Silva, Maria R.r. [UNIFESP], Kerbauy, José [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S1516-84842001000200002
http://repositorio.unifesp.br/handle/11600/1222
Resumo: Bone marrow biopsy allows evaluation of cellularity, abnormal localization of immature precursors and fibrosis in myelodysplastic syndrome. It has been considered important to make diagnosis and prognosis of this disorder. The object of this study evaluated the influence of histopathological parameters, such as cellularity, erythroid/myeloid ratio, abnormal localization of immature precursors and marrow fibrosis, on survival of myelodysplastic syndrome patients. Forty-six patients, admitted from April 1985 to June 1998, and diagnosed as being myelodysplastic syndrome according to French-American-British criteria, were selected. There were 20 males and 26 females, with median age of 61 years. Forty-six bone marrow smears and 36 trephine biopsies were reviewed. Mean survival of hypocellular cases was 64.8 months and of hyper and normocellular cases was 31.8 months. Patients with predominance of erythroid hyperplasia had mean survival of 50.8 months, greater than those with predominance of myeloid hyperplasia (20.3 months). There was no statistical difference in survival of patients with or without abnormal localization of immature precursors and with or without marrow fibrosis. Bone marrow biopsy is a useful tool for the identification of parameters that influence prognosis in myelodysplastic syndrome. Hypocellularity and erythroid hyperplasia were correlated with longer survival while myeloid hyperplasia with poorer survival.
id UFSP_82bea10abbca75874ba5cbb36ccc5bd2
oai_identifier_str oai:repositorio.unifesp.br/:11600/1222
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Myelodysplastic syndromes: histopathology as prognostic factorSíndromes mielodisplásicas: a histopatologia como fator prognósticoMyelodysplastic syndromehistopathologyprognosticSíndrome mielodisplásicahistopatologiaprognósticoBone marrow biopsy allows evaluation of cellularity, abnormal localization of immature precursors and fibrosis in myelodysplastic syndrome. It has been considered important to make diagnosis and prognosis of this disorder. The object of this study evaluated the influence of histopathological parameters, such as cellularity, erythroid/myeloid ratio, abnormal localization of immature precursors and marrow fibrosis, on survival of myelodysplastic syndrome patients. Forty-six patients, admitted from April 1985 to June 1998, and diagnosed as being myelodysplastic syndrome according to French-American-British criteria, were selected. There were 20 males and 26 females, with median age of 61 years. Forty-six bone marrow smears and 36 trephine biopsies were reviewed. Mean survival of hypocellular cases was 64.8 months and of hyper and normocellular cases was 31.8 months. Patients with predominance of erythroid hyperplasia had mean survival of 50.8 months, greater than those with predominance of myeloid hyperplasia (20.3 months). There was no statistical difference in survival of patients with or without abnormal localization of immature precursors and with or without marrow fibrosis. Bone marrow biopsy is a useful tool for the identification of parameters that influence prognosis in myelodysplastic syndrome. Hypocellularity and erythroid hyperplasia were correlated with longer survival while myeloid hyperplasia with poorer survival.A biópsia de medula óssea propicia a avaliação da celularidade global, dos precursores imaturos de localização anormal e de fibrose nas sídromes mielodisplásicas. O método tem sido considerado importante também para o diagnóstico e prognóstico da síndrome. O objetivo deste estudo foi o de observar a influência de parâmetros histológicos como a celularidade, a relação eritróide-mielóide, a presença de precursores imaturos de localização anormal e fibrose medular na sobrevida de pacientes com a síndrome. De abril de 1985 a junho de 1998, 46 pacientes diagnosticados segundo os critérios do grupo Franco, Americano, Britânico foram estudados. A casuística era composta de 20 pacientes do sexo masculino e de 26 do sexo feminino com idade média de 61 anos. Foram revisados 46 esfregaços de aspirado de medula óssea e 36 cortes histológicos de biópsia de medula óssea. A sobrevida média dos casos de hipocelularidade foi de 64,8 meses e dos casos que eram hiper ou normocelulares foi de 31.8 meses. Pacientes com a predominância de hiperplasia tiveram sobrevida média de 50,8 meses, que foi superior aos que apresentavam hiperplasia mielóide (20,3 meses). Não houve diferença estatística na sobrevida dos pacientes que apresentaram ou não fibrose medular. A biópsia de medula óssea deve ser considerada útil na identificação de parâmetros que influenciam no prognóstico da síndrome mielodisplásica. A hipocelularidade e a hiperplasia eritrocitária está relacionada com a sobrevida maior, enquanto a hiperplasia mielóide com a sobrevida mais curta.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Hematologia e HemoterapiaUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de Patologia AplicadaUNIFESP, EPM, Hematologia e HemoterapiaUNIFESP, EPM, Depto. de Patologia AplicadaSciELOAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularUniversidade Federal de São Paulo (UNIFESP)Romeo, Maura [UNIFESP]Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]Silva, Maria R.r. [UNIFESP]Kerbauy, José [UNIFESP]2015-06-14T13:29:28Z2015-06-14T13:29:28Z2001-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion63-68application/pdfhttp://dx.doi.org/10.1590/S1516-84842001000200002Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 23, n. 2, p. 63-68, 2001.10.1590/S1516-84842001000200002S1516-84842001000200002.pdf1516-8484S1516-84842001000200002http://repositorio.unifesp.br/handle/11600/1222engRevista Brasileira de Hematologia e Hemoterapiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-06T07:31:58Zoai:repositorio.unifesp.br/:11600/1222Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-06T07:31:58Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Myelodysplastic syndromes: histopathology as prognostic factor
Síndromes mielodisplásicas: a histopatologia como fator prognóstico
title Myelodysplastic syndromes: histopathology as prognostic factor
spellingShingle Myelodysplastic syndromes: histopathology as prognostic factor
Romeo, Maura [UNIFESP]
Myelodysplastic syndrome
histopathology
prognostic
Síndrome mielodisplásica
histopatologia
prognóstico
title_short Myelodysplastic syndromes: histopathology as prognostic factor
title_full Myelodysplastic syndromes: histopathology as prognostic factor
title_fullStr Myelodysplastic syndromes: histopathology as prognostic factor
title_full_unstemmed Myelodysplastic syndromes: histopathology as prognostic factor
title_sort Myelodysplastic syndromes: histopathology as prognostic factor
author Romeo, Maura [UNIFESP]
author_facet Romeo, Maura [UNIFESP]
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
Silva, Maria R.r. [UNIFESP]
Kerbauy, José [UNIFESP]
author_role author
author2 Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
Silva, Maria R.r. [UNIFESP]
Kerbauy, José [UNIFESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Romeo, Maura [UNIFESP]
Chauffaille, Maria de Lourdes Lopes Ferrari [UNIFESP]
Silva, Maria R.r. [UNIFESP]
Kerbauy, José [UNIFESP]
dc.subject.por.fl_str_mv Myelodysplastic syndrome
histopathology
prognostic
Síndrome mielodisplásica
histopatologia
prognóstico
topic Myelodysplastic syndrome
histopathology
prognostic
Síndrome mielodisplásica
histopatologia
prognóstico
description Bone marrow biopsy allows evaluation of cellularity, abnormal localization of immature precursors and fibrosis in myelodysplastic syndrome. It has been considered important to make diagnosis and prognosis of this disorder. The object of this study evaluated the influence of histopathological parameters, such as cellularity, erythroid/myeloid ratio, abnormal localization of immature precursors and marrow fibrosis, on survival of myelodysplastic syndrome patients. Forty-six patients, admitted from April 1985 to June 1998, and diagnosed as being myelodysplastic syndrome according to French-American-British criteria, were selected. There were 20 males and 26 females, with median age of 61 years. Forty-six bone marrow smears and 36 trephine biopsies were reviewed. Mean survival of hypocellular cases was 64.8 months and of hyper and normocellular cases was 31.8 months. Patients with predominance of erythroid hyperplasia had mean survival of 50.8 months, greater than those with predominance of myeloid hyperplasia (20.3 months). There was no statistical difference in survival of patients with or without abnormal localization of immature precursors and with or without marrow fibrosis. Bone marrow biopsy is a useful tool for the identification of parameters that influence prognosis in myelodysplastic syndrome. Hypocellularity and erythroid hyperplasia were correlated with longer survival while myeloid hyperplasia with poorer survival.
publishDate 2001
dc.date.none.fl_str_mv 2001-08-01
2015-06-14T13:29:28Z
2015-06-14T13:29:28Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S1516-84842001000200002
Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 23, n. 2, p. 63-68, 2001.
10.1590/S1516-84842001000200002
S1516-84842001000200002.pdf
1516-8484
S1516-84842001000200002
http://repositorio.unifesp.br/handle/11600/1222
url http://dx.doi.org/10.1590/S1516-84842001000200002
http://repositorio.unifesp.br/handle/11600/1222
identifier_str_mv Revista Brasileira de Hematologia e Hemoterapia. Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, v. 23, n. 2, p. 63-68, 2001.
10.1590/S1516-84842001000200002
S1516-84842001000200002.pdf
1516-8484
S1516-84842001000200002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 63-68
application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1824718198114615296